TMOi001-A-11
General
Cell Line |
|
| hPSCreg name | TMOi001-A-11 |
| Cite as: | TMOi001-A-11 (RRID:CVCL_D0MY) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
TMOi001-A (Gibco Episomal iPSC Line; A18945) TMOi001-A-1 (hiPSC-CD34-GFP-3G6) TMOi001-A-6 (DISC1 Ex2 C4) TMOi001-A-5 (DISC1 Ex2 D5) TMOi001-A-4 (SPG11_HA) WAe009-A-1E (TBX20-KO) |
| Last update | 25th August 2023 |
| Notes | We generated an human induced pluripotent stem cell line with a homozygous deletion in the SYNM gene by CRISPR/Cas9 genome editing. This line is a synemin knock-out obtained from Episomal hiPSC. |
| User feedback | |
Provider |
|
| Generator |
INSERM (INSRM)
Contact:
INSERM (INSRM) |
| Owner | INSERM (INSRM) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA114304151 |
| Cellosaurus | CVCL_D0MY |
| Wikidata | Q123033621 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104619829 |
Ethics
Also have a look at the ethics information for the parental line
TMOi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
TMOi001-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
Unknown |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method | Enzyme-free cell dissociation | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ Plus
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
INSRMi017-A-11.tif
Morphology of the hiPS colony
Differentiation Potency
Microbiology / Virus Screening |
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: 45
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.